Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures

Sameer K Khan, Ajay Malviya, Scott D Muller, Ian Carluke, Paul F Partington, Kevin P Emmerson, Mike R Reed, Sameer K Khan, Ajay Malviya, Scott D Muller, Ian Carluke, Paul F Partington, Kevin P Emmerson, Mike R Reed

Abstract

Background and purpose: Enhanced Recovery (ER) is a well-established multidisciplinary strategy in lower limb arthroplasty and was introduced in our department in May 2008. This retrospective study reviews short-term outcomes in a consecutive unselected series of 3,000 procedures (the "ER" group), and compares them to a numerically comparable cohort that had been operated on previously using a traditional protocol (the "Trad" group).

Methods: Prospectively collected data on surgical endpoints (length of stay (LOS), return to theater (RTT), re-admission, and 30- and 90-day mortality) and medical complications (stroke, gastrointestinal bleeding, myocardial infarction, and pneumonia within 30 days; deep vein thrombosis and pulmonary embolism within 60 days) were compared. Results ER included 1,256 THR patients and 1,744 TKR patients (1,369 THRs and 1,631 TKRs in Trad). The median LOS in the ER group was reduced (3 days vs. 6 days; p = 0.01). Blood transfusion rate was also reduced (7.6% vs. 23%; p < 0.001), as was RTT rate (p = 0.05). The 30-day incidence of myocardial infarction declined (0.4% vs. 0.9%; p = 0.03) while that of stroke, gastrointestinal bleeding, pneumonia, deep vein thrombosis, and pulmonary embolism was not statistically significantly different. Mortality at 30 days and at 90 days was 0.1% and 0.5%, respectively, as compared to 0.5% and 0.8% using the traditional protocol (p = 0.03 and p = 0.1, respectively).

Interpretation: This is the largest study of ER arthroplasty, and provides safety data on a consecutive unselected series. The program has achieved a statistically significant reduction in LOS and in cardiac ischemic events for our patients, with a near-significant decrease in return to theater and in mortality rates.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3940988/bin/ORT-85-26-g001.jpg
This schematic diagram shows the patient’s progression through different components of the Enhanced Recovery program.

References

    1. Abuzakuk TM, Coward P, Shenava Y, Kumar VS, Skinner JA. . Int Wound J. 2006;3(2):133–7.
    1. Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. . J Bone Joint Surg (Br) 2011;93(12):1577–85.
    1. Aveline C, Leroux A, Vautier P, Cognet F, Le Hetet H, Bonnet F. . Ann Fr Anesth Reanim. 2009;28(9):728–34.
    1. Brämer GR. . World Health Stat Q. 1988;41(1):32–6.
    1. Clarke JV, Deakin AH, Dillon JM, Emmerson S, Kinninmonth AW. . J Wound Care. 2009;18(1):5–8. 10–1.
    1. Department of Health. Health Service Circular HSC 2007/001. Better blood transfusion– Safe and appropriate use of blood. London. 2007.
    1. Holm B, Kristensen MT, Bencke J, Husted H, Kehlet H, Bandholm T. . Arch Phys Med Rehabil. 2010;91:1770–6.
    1. Husted H, Holm G, Jacobsen S. . Acta Orthop. 2008;79(2):168–73.
    1. Husted H, Hansen HC, Holm G, Bach-Dal C, Rud K, Andersen KL, Kehlet H. . Arch Orthop Trauma Surg. 2010a;130(2):263–8.
    1. Husted H, Otte KS, Kristensen BB, Orsnes T, Kehlet H. . Arch Orthop Trauma Surg. 2010b;130(9):1185–91.
    1. Husted H, Otte KS, Kristensen BB, Ørsnes T, Wong C, Kehlet H. . Acta Orthop. 2010c;81(5):599–605.
    1. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. . J Bone Joint Surg (Br) 2011;93(1):91–5.
    1. Jones R. Costing orthopaedic interventions. Br J Healthcare Management. 2008;14(12):539–47.
    1. Jones S, Alnaib M, Kokkinakis M, Wilkinson M, St Clair Gibson A, Kader D. . Ann R Coll Surg Engl. 2011;93(1):71–5.
    1. Larsen K, Hansen TB, Søballe K, Kehlet H. . Health Qual Life Outcomes. 2010;8:144.
    1. Malviya A, Martin K, Harper I, Muller SD, Emmerson KP, Partington PF, Reed MR. . Acta Orthop. 2011;82(5):577–81.
    1. National Electronic Library for Medicines. London and South East Regional Medicines Information Service. 2010 Jan 25; Accessed 20 February 2013.
    1. National Institute for Health and Care Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. . 2007 (Clinical guideline CG46) Accessed 15 May 2013.
    1. National Institute for Health and Care Excellence. Venous thromboembolism: reducing the risk. . 2011 (Clinical guideline CG92) Accessed 15 May 2013.
    1. Nechleba J, Rogers V, Cortina G, Cooney T. . J Knee Surg. 2005;18(3):197–202.
    1. NHS Blood and Transplant. Strategic Plan 2012 – 2017. (date last accessed 10 Aug 2012)
    1. NHS Connecting for Health. OPCS Classification of Interventions and Procedures. Version 4.5. London: TSO, 2009.
    1. Schroer WC, Diesfeld PJ, LeMarr AR, Reedy ME. Benefits of prolonged postoperative cyclooxygenase-2 inhibitor administration on total knee arthroplasty recovery: a double-blind, placebo-controlled study. J Arthroplasty (6 Suppl) 2011;26:2–7.
    1. Sprowson A, Symes T, Khan SK, Oswald T, Reed MR. . Surgeon. 2012 Epub ahead of print.
    1. Sukeik M, Alshryda S, Haddad FS, Mason JM. . J Bone Joint Surg (Br) 2011;93(1):39–46.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren